Abstract Hepatitis C virus (HCV) is one of the major causes of hepatocellular carcinoma (HCC) around the world. HCV promotes characteristics of cancer stem cells and the infected cells are insensitive to apoptotic signals, which lead to persistent antigen stimulation and T cell exhaustion in the host. In spite of new effective antiviral drugs, new challenges are around the corner as drugresistant viral strains and drug-drug interactions have already been reported. Considering that there are few effective treatments available for HCC, novel immunotherapies to prevent HCC and late stage HCV-related liver diseases should be considered. Given that adoptive immunotherapy with antigen-specific T lymphocytes has emerged as an effective therapeutic strategy for combating cancer, there is, therefore, reason to examine the possibility of using highly functional HCV-reactive T cells in immunotherapy. This review aims to provide the current understanding of natural HCV responding T cells in HCV infection and to give an update on the novel approaches that have the capacity to ex vivo generate functional T cells for potential adoptive cell therapy. Approaches based on the pMHC tetramer-associated magnetic enrichment, exogenous HCV T cell receptor transfer, and induced pluripotent stem cell technologies are described herein. Their potentials as immunotherapeutic against HCV-related diseases are discussed.
Introduction
Hepatitis C virus (HCV) is one of the major causes of chronic liver disease and it is estimated that around 170 million people in the world are infected. The problem with HCV infection is the persistence of the virus that leads to liver cirrhosis and the increased risk of hepatocellular carcinoma, and today this has become a leading cause for liver transplantation. The available therapy involves a combination of pegylated interferon (IFN)-a, ribavirin and, since their introduction in 2011, NS3/4A protease inhibitors for genotype 1 virus (Jacobson et al. 2011) . A major challenge is patients who do not respond to treatment, where HCV genotype 1 (in particular subtype A), advanced fibrosis, high viral load or IL28B SNP non-CC are regarded as important negative baseline factors (Ghany et al. 2011) . Given the reported side effects and potential drug-drug interactions, current therapies with direct acting anti-virals (DAAs) against HCV are not approved for several patient groups (decompensated liver cirrhosis, liver transplantation, severe psychiatric illness etcetera) (Sarrazin et al. 2012) . Thus, improved interventions for hard-to-treat HCV patients are crucial.
HCV has adapted several mechanisms to escape host immunity. Many of the viable variants cluster in high-variability regions (e.g., HVR1) of the viral glycoproteins, providing flexibility for adaptation against host humoral immunity. Not only the fact that the access of the epitopes to antibody neutralization sites is concealed by glycosylation sites, the presence of interfering antibodies may also disturb the action of neutralizing antibodies. It was thought earlier that antibodies attributed only a marginal role to the humoral response during HCV infection (Chen et al. 1999; Logvinoff et al. 2004; Netski et al. 2005) . However, experimental models have shown that neutralizing antibodies act in a strain-and isolate-specific manner and prevent HCV infection in chimpanzees (Farci et al. 1994 (Farci et al. , 1996 . More recent studies have elegantly shown that improved vaccination strategies employing for instance virus-like particles, pseudotyped for HCV proteins, can trigger broadly neutralizing antibodies in macaques and a human liver-chimeric mouse model (Dorner et al. 2011; Garrone et al. 2011; Giang et al. 2012; Law et al. 2008) . Broadly neutralizing antibodies have substantial prophylactic and therapeutic potentials; therefore, they are the holy grail in the development of a prophylactic vaccine to enhance clearance of acute HCV infections. However, because most chronically infected patients have poor HCV-specific T cell responses but substantial levels of neutralizing antibodies, therapeutic approaches have mainly focused on enhancing the cellular arm of the adaptive immune response.
A critical property of adaptive immunity is the T cell memory that instructs the immune system to act more rapidly and effectively upon re-exposure to the same pathogen (Antia et al. 2005) . In chronic viral infections, where antigen and/or inflammation persist for many years, various levels of exhaustions have been found in virusspecific T cells. This immunological phenomenon defined as ''T cell exhaustion'' was first proposed for chronic lymphocytic choriomeningitis virus infection in mice, and it has also been validated in other chronic viral infections in humans, including the human immunodeficiency virus (HIV), hepatitis B virus, human papilloma virus and HCV (Wherry 2011) . Studies have demonstrated that virus-specific T cell responses play a major role in the outcome of HCV infection (Bowen and Walker 2005; Grakoui et al. 2003; Rehermann and Nascimbeni 2005) . It seems clear that a broad and long-lasting CD4
? and CD8 ? T cell response is required to control HCV, but many additional details remain unclear.
This review presents the main features of HCV responding T cells during natural infection, and gives an introduction over recent new strategies on ex vivo generation of highly functional antigen-specific T cells that may have an impact for adoptive cell therapies of HCV infection.
Responding T Cells in HCV Infection
Acute HCV Infection with Spontaneous Resolution Both HCV-specific CD4
? and CD8 ? T cells are determinant for the outcome of HCV infection. At the time of clinical symptoms during acute HCV infection, extensive proliferation of HCV-specific CD4
? and CD8 ? T cells with concomitant interleukin (IL)-2 and IFN-c production has often been detected in the blood of patients who later overcome the infection. These responses emerge four to 6 weeks after infection targeting multiple viral epitopes and are sustained for many years after viral resolution. In this early phase, the activated CD8
? cytotoxic T lymphocyte (CTL) populations may acquire a ''stunned'' phenotype, in which they temporarily fail to proliferate and secrete IFN-c but recover as the HCV viremia declines (Lechner et al. 2000; Rehermann 2009; Thimme et al. 2001) . A rapid emergence of T helper responses in concert with CTL responses in the early disease often demonstrates a strong and persistent CTL response in resolving acute HCV infection. As for other viral infections, an efficient T cell response with poly-functionality has also been shown to correlate with resolution of HCV infection (Abdel-Hakeem et al. 2010; Badr et al. 2008; Ciuffreda et al. 2008; Zimmerli et al. 2005) . According to the definition of antigen-experienced T cells (Sallusto et al. 2004) , the functional attributes of HCV-specific effector T cells in these patients resemble T cells that derive from the naïve and memory T cell (T CM : central memory, or T EM : effector memory) pools. As illustrated in Fig. 1 , the virus-specific T cells at this stage are able to differentiate into highly effective polyfunctional effector T cells that have substantial capacity to secrete antiviral cytokines, capable of homing to infected tissue and proliferating to drive the elimination of infected cells. CD8
?
CTLs are essential for an effective immune response against all viral infections (Appay et al. 2008) and it is known that virus-specific CTLs mediate viral suppression by three main pathways using: (1) antiviral mechanisms of IFN-c; (2) lysis of infected cells via Fas-FasL interaction; and (3) lysis of target cells by delivery of granzyme and perforin. Albeit in the case for HCV, the non-cytolytic mechanism of viral clearance has been discussed as an alternative pathway in viral hepatitis since infected cells could be cured instead of killed and, therefore, cause less liver injury (Guidotti and Chisari 2001; Guidotti et al. 1999 ).
Chronic Persistent HCV Infection
In contrast to patients who spontaneously resolve their HCV infection, those who progress to the chronic phase of infection show an reduced HCV-specific CD4
? T cell response relatively early in the acute phase of infection. In patients developing chronic infection, virus-specific CD8 ? T lymphocytes are reported as abnormal in terms of their synthesis of antiviral cytokines and lytic activity. In addition, it is noted later on in the chronic phase of infection that most of the T cell responses were detectable only in the liver but not in peripheral blood, indicating T cell accumulation and enrichment at the site of disease. In spite of this, only a small fraction, as low as 0-5 %, of CD8 liver T cells appears to be HCV-specific (mean: 0.4 %) (Neumann-Haefelin et al. 2008; Spangenberg et al. 2005 ). Thus, it seems that the majority of CD8
? T cells in the liver are not HCV-specific in chronically infected patients. Based on these findings, HCV-specific T cells are thus referred to as dysfunctional and lack both poly-functionality and multiple target specificity (Kim and Ahmed 2010; Klenerman and Thimme 2012) . The basis for this is thought to be the continuous antigen stimulation as a consequence of the chronic HCV infection, which drives the HCV-specific T cells into exhaustion. Considering that up to 30 % of the liver could be infected with HCV, adaptive T cell immunity may not be sufficient in the majority of patients. This allows development of viral variants known as ''viral escape mutants'', a key viral mechanism that further supports the persistent infection. As illustrated in Fig. 1 , exhausted T cells represent terminally differentiated effector T cells; functional impairment includes limited capacity to (1) produce antiviral cytokines, (2) kill the target cells, (3) proliferate to self-renew themselves and (4) express inhibitory receptors. It is known that T cell inhibitory receptors, such as PD-1, play a major role in CD8
? T cell exhaustion and may drive the effector cells to full exhaustion with ultimately CD8
? T cell depletion at the end (Wherry 2011) . Attempts to block the PD-1/PD-L1 pathway led only to partial restoration of T cell function and furthermore it was found that HCV-specific CD8
? T cells with a very high expression of PD-1 were highly susceptible to apoptosis (Radziewicz et al. 2007 (Radziewicz et al. , 2008 , and were refractory to PD-1/PD-L1 blockade especially in the liver (Nakamoto et al. 2008) . Recent work additionally indicates that PD-1 is not the only inhibitory receptor involved in T cell exhaustion but there appears to be a more complex network of inhibitory receptors including 2B4 and CD160 KLRG1, CTLA-4 and Tim-3 that all can contribute to T cell dysfunction in chronic HCV infections (Klenerman and Thimme 2012) . Furthermore, mechanisms contributed by T regulatory cells and viral escape are operational and favor the persistence of HCV. Of note, though HCV is prone to viral escape, it has been suggested that viral escape may not be a universal mechanism and in fact is limited by fitness cost, for example by the inability to tolerate mutations within highly constrained epitopes (Klenerman and Thimme 2012) .
Antigen Responding T Cells in Adoptive Cell Transfer Immunotherapy
Adoptive cell transfer (ACT) immunotherapy of T cells has emerged as a promising advance in cancer immunotherapy.
As a therapy to treat cancer ACT relies on the natural ability of CD8 ? T cells to attack tumors for example (Restifo et al. 2012 ). Similar to chronic viral infections, the resilient persistence of tumor growth also causes CD8
? T cells to become both exhausted and senescent (Klebanoff et al. 2006) . In ACT, tumor-specific lymphocytes either harvested from a patient's tumor or genetically modified to confer tumor specificity are prepared and infused back into the same patient (Fig. 2) . Remarkably, up to 72 % of patients with advanced stage IV melanoma have shown an objective clinical response to their metastatic disease (Restifo et al. 2012) . Recent studies have also indicated that transfer of less-differentiated memory or stem cell-like CD8
? T cells correlates with a more robust eradication of the tumor (Klebanoff et al. 2011; Wang et al. 2012) . Considering that features of responding T cells in cancer and chronic infection share great resemblance, such as functional impairment and an immunosuppressive environment, it is interesting to learn that curative treatment for tumors has advanced considerably since the introduction of ACT using tumor-responding T cells (Restifo et al. 2012 ). In the light of clinical and translational tumor studies, we summarize below some recent advances by which the production or enrichment of functional HCV-specific T cells with therapeutic implications has been shown to be feasible.
Recent Advances in the Generation of Highly Functional HCV Responding T Cells

Enrichment by pMHC-I Tetramer
Based on theoretical extrapolations from animal studies, the adult human may have up to 3 9 10 11 naïve phenotype T cells. Alanio et al. (2010) and Schmidt et al. (2011) proposed to enrich functional and active virus-specific CD8
? T cells directly from the naïve pool of antigenspecific precursors because the human T cell repertoire is already equipped with a substantial range of antigen-specific T cells. Using an enrichment protocol based on pMHC class I tetramer technology referred as tetramer-associated magnetic enrichment (TAME) (Alanio et al. 2010) , both groups were able to successfully enrich HCV-specific CTLs captured by the NS3 1406-1415 pMHC tetramer from peripheral blood cells of healthy blood donors. As expected, the enriched T cells displayed a naïve phenotype, including high surface expression of CD45RA, CD27 and CCR7 and low expression of CD11a (Schmidt et al. 2011 ). The captured HCV-specific T cells could further be matured and expanded after stimulation with autologous Fig. 2 Current concepts of adoptive cell therapy (ACT) and T cell modification. Patient's own T cells are modified in vitro to increase or acquire targetspecific receptors that provide them ability to eliminate target cells dendritic cells loaded with NS3 1406-1415 peptide. Importantly, despite that T cells originate from HCV-negative blood donors, the expanded T cells displayed a robust antiviral efficacy and were able to inhibit the replication of HCV replicon on Huh7 A2 HCV hepatoma cells pulsed with the cognate viral peptide (Schmidt et al. 2011) . In summary, this approach allowed a rapid isolation of highly functional and proliferative HCV-specific T cells from blood donors and the possibility to expand them with autologous dendritic cells to drive them into effector memory T cells that could give rise to highly functional T cells. Thus, it has substantial implications for adoptive T cell therapy for HCV patients.
Transfer of Exogenous T Cell Receptor
This approach relied on T cell receptor (TCR) transfer by which antigen specificity could be transferred from one T cell to another through gene transfer. TCR transfer has led to the generation of a number of TCR transgenic and retrogenic animal models for viral hepatitis research (Bettini et al. 2012; Chen et al. 2000 Chen et al. , 2004 Chen et al. , 2005 . As a result and based on a similar principle, TCR-redirected T cells have also emerged as a new possibility to treat tumor patients (Restifo et al. 2012 ). In the case of HCV, several ab TCRs have been cloned from human and mouse CD8
? T cell lines that are specific to HLA-A2-restricted immunodominant CTL epitopes within the HCV NS3 and NS5A viral proteins (Callender et al. 2006; Pasetto et al. 2012a, b; Zhang et al. 2010) . The retroviral-mediated vector technology was utilized to transfer new TCRs (isolated from HCV patients or HCV vaccinated HLA-transgenic mice) to healthy T cells from blood donors, as well as from HCVinfected individuals. To date, HCV TCRs with specificity to the immunodominant HLA-A2 restricted CTL epitopes NS3 1073 -1081 , NS3 1406 -1415 or NS5A 1992 have been identified and successfully restored on human T cells. By this approach, the modified recipient T cells acquired ability to respond not only to HCV peptide-loaded target cells but also to HCV replicon-positive hepatoma cells directly without having to pulse them with exogenous HCV peptide. In these studies, HCV TCR-modified T cells recognized HCV target cells with a poly-functional response (IFN-c, TNF-a and IL-2 production and CD107a up regulation). Pasetto et al. (2012a, b) further demonstrated that HCV TCR-redirected T cells effectively inhibited HCV replication on HCV replicon cells (HCV ? HLA-A2 ? Huh-7 hepatoma cells) and that this inhibition could utilize the cytolytic or non-cytolytic mechanism. In this regard, the cytolytic mechanism used by the high avidity NS3-specific T cells (TCR H4 or TCR F8) was highly sensitive to its viral peptide target and they are highly poly-functional. Elimination of HCV replicon by such T cells was associated with cellular death of HCV replicon cells, which is in sharp contrast to the low avidity NS5A T cells (TCR 19 or TCR 69) that display features resembling non-cytolytic CTLs in their response to HCV replicon cells. It was shown that NS5A T cells are able to spare the infected cells from cell death compared to the high avidity NS3 T cells. In contrast, NS5A T cells showed a preference to IFN-c secretion and no sign of CD107a degranulation; though the inhibition of HCV RNA replication was rapid and effective, the sign of cell death or cell damage was limited.
Even though cytolytic/high avidity TCRs may be more effective in eliminating HCV ? target cells, there are benefits in acquiring non-cytolytic T cells, as it may spare the host from unwanted tissue damage by having less hepatotoxic potentials (Pasetto et al. 2012a ). Adding antigenspecific low avidity T cells might be an advantage when reconstituting a multi-specific antiviral T cell response when the potential overkilling of hepatocytes is a concern; however, the ultimate answer to which of the T cells are more beneficial remains to be evaluated in vivo.
The analysis of T cell memory markers (Lamana et al. 2004) T cells was recently developed (Yang et al. 2010 (Yang et al. , 2012 . In those studies, central memory-like CD8
? T cells could be generated in clinical-scale using a simplified method based on lentiviral gene transfer, and the delivered antitumor TCR yielded up to 600fold expansion of CD8 T cells within 12 days. Importantly, they reported that specific cytokine combinations IL-12 plus IL-7 or IL-21 yielded the phenotype of CD62L high CD28 high CD127 high CD27-high CCR7
high , which can be associated with lessdifferentiated T cells that resemble T CM . Moreover, TCRengineered CD8
? T cells conferred specific antitumor activity and many displayed a central memory-like phenotype.
Given the current molecular technology and synthetic genetics, there is a large potential with this approach. Not only the expression, avidity and longevity of the TCRs that can be controlled in detail, but it is also possible to provide additional co-stimulatory receptors or tissue homing receptors to govern the strength of CTLs. Such modifications may also improve their capacity to home to infected cells and to deliver drugs in a site-specific manner. Arch. Immunol. Ther. Exp. (2014) 62:23-30 27 Rejuvenation by Induced Pluripotent Stem Cell Technology
Regeneration of antigen-specific T cells has recently been explored with induced pluripotent stem cells (iPSC) technology. After the discovery that somatic cells can be reprogrammed into iPSCs via the introduction of Yamanaka factors, this approach has not been subjected to same ethical concerns as that for embryonic stem cells (ESCs) (Takahashi and Yamanaka 2006) . Similar to ESCs, iPSCs have the capacity for self-renewal and could potentially derive unlimited induction of antigen-specific juvenile T cells. Two stem cell groups have explored this novel approach to reprogram an exhausted immune system as treatment of cancer and chronic infection (Nishimura et al. 2013; Vizcardo et al. 2013 ). Both groups successfully established protocols to reprogram human antigen-specific CD8 ? mature T cells (T cell clones) into iPSCs. (Nishimura et al. (2013)) focused their work on HIV-specific T cells using Sendai virus vectors encoding reprogramming factors OCT3/4, SOX2, KLF4, and c-MYC or SV40 large T antigen. They managed to reprogram a clonally expanded HIV Nef-specific CD8
? CTL clone from a HIV-1-infected patient to pluripotency and report the conditions they developed to reprogram several CD8
? or CD4 ? T cell clones that were specific for epitopes within the cytomegalovirus, glutamic acid decarboxylase antigen in type 1 diabetes, and a-GalCer. It was revealed that T cell-derived iPSCs were re-differentiated into CD8
? T cells and showed a high proliferative capacity and elongated telomeres. Similar technology was used by Vizcardo et al. (2013) who showed that iPSCs could be produced from a mature CTL clone specific for the melanoma epitope MART-1. Longterm cultured tumor infiltrated lymphocytes derived from a melanoma patient were reprogrammed into iPSCs after sendai viral transduction with the four Yamanaka reprogramming factors, and could be further differentiated into functional IFN-c secreting MART-1 reactive CD8
? T cells. The strength with this approach is that iPSCs keep the ability to re-express its parental antigen-specific TCR. Both studies illustrated that the same productive of TCR gene rearrangement was found in all reprogrammed and re-differentiated CD8
? T cells. There was also evidence that such ''rejuvenated'' cells possessed antigen-specific killing activity and exhibited TCR gene rearrangement patterns identical to those of the original T cell clone from the patient (Nishimura et al. 2013 ). Furthermore, they showed that re-differentiation of these cells produced CD8
? T cells that recognized their original cognate antigen and had features of rejuvenated cells so critically needed to improve the efficacy of T cell-based therapies for the treatment of cancer and viral-associated diseases As a proof of concept, the results presented by these studies are exciting and more data are now warranted to justify the in vivo effect and safety of iPSCs technology.
Conclusions
The immune system is capable of achieving protective immunity and of inducing long-term, durable pathogenspecific responses. The use of adoptive T cell-based therapies to eradicate malignancies is a meaningful merger of basic immunology and clinical therapy that could have a therapeutic impact for HCV patient groups that are refractory of standard therapy. These may also serve in new therapeutic combinations, for instance with antiviral drugs to meet the potential challenges from resistant virus strains. Treatment for hepatitis C is moving forward, almost every week new data appear on how DAAs succeed or fail in clinical trials. Although encouraging data are constantly emerging, there are still hard-to-treat populations with poor rates of sustained virological response (SVR: cured infection); for instance, SVR rates in cirrhotic patients are only 47 % (Gilead Sciences 2013). Importantly, with DAAs, viral resistance mutations are readily detected in the target protein, which explains the lack of efficacy once they occur. New treatment strategies with combinations of several DAAs will be used to overcome emergence of resistance; however, it has been questioned if such combinations will be tolerated (Sarrazin et al. 2012 ). Thus, novel interventions for hard-to-treat HCV patients are needed. With T cell therapy becoming a reality for cancer patients, it will also be possible to provide highly functional therapeutic T cells to HCV patients, regardless of their immune status to cure HCV-related liver disease in difficult-to-treat patient groups.
